Online inquiry

IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14647MR)

This product GTTS-WQ14647MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets DLL3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016941.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10683
UniProt ID Q9NYJ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14647MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6878MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ8907MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ11141MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ13894MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ7907MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ2332MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ14193MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ10607MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW